Trials / Suspended
SuspendedNCT04700488
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
MRI Imaging to Predict Outcomes of Treatment in PDAC Patients
- Status
- Suspended
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Cedars-Sinai Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).
Detailed description
The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 6D-MRI | Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI |
Timeline
- Start date
- 2022-05-19
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
- First posted
- 2021-01-08
- Last updated
- 2025-12-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04700488. Inclusion in this directory is not an endorsement.